Yubo Reports Zero Revenue, $563K Loss, and Going Concern Warning
YBGJ sits 80% above its 52-week low of $0.007.
Summary
Yubo International Biotech's Q2 2026 10-Q shows no revenue, a $563,747 six-month loss, and a going concern warning. The company has only $11,989 in cash and depends on shareholder support to stay afloat.
Key Events · Earnings and Guidance · YBGJ
-
Zero Revenue Reported
Sales were $0 for both the three and six months ended June 30, 2026, unchanged from the prior year periods.
-
Net Loss of $563,747
Six-month net loss attributable to common stockholders was $520,557, with total net loss of $563,747.
-
Going Concern Warning
Cash of $11,989 and negative working capital of $2,744,500 raise substantial doubt about the company's ability to continue as a going concern.
-
Shareholder Support Letter
On March 31, 2026, largest shareholder Jun Wang agreed to provide continuous financial support for 12 months to meet liabilities as they fall due.
Analysis · YBGJ · Industrial Applications And Services
Yubo International Biotech reported zero revenue for the first half of 2026 and a net loss of $563,747. Cash stands at just $11,989 with negative working capital of $2.7 million. The company reiterates substantial doubt about its ability to continue as a going concern, relying on a financial support letter from its largest shareholder to fund operations through March 2027.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, YBGJ was trading at $0.01 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.01 to $1.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.